Chronic lymphocytic leukaemia: a step ahead in the journey toward eradication
Mené sur 49 patients atteints d'une leucémie lymphoïde chronique réfractaire ou récidivante, cet essai de phase Ib évalue les caractéristiques pharmacocinétiques, l'activité antitumorale, la dose maximale tolérée et la toxicité du vénétoclax en combinaison avec du rituximab
Chronic lymphocytic leukaemia has been the “Cinderella” of haematological neoplasms for many decades, with little understanding of its molecular pathogenesis, scant innovation in treatment options, and little hope of eradication. However, this scenario has changed substantially during the past few years, and continues to change at a sustained pace.1 In the Lancet Oncology, John Seymour and colleagues2 report the findings of their phase 1b study investigating the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody rituximab in adult patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma
The Lancet Oncology , commentaire, 2016